UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Expansion of Fcγ Receptor IIIa–Positive Macrophages, Ficolin 1–Positive Monocyte‐Derived Dendritic Cells, and Plasmacytoid Dendritic Cells Associated With Severe Skin Disease in Systemic Sclerosis

Arthritis & rheumatology (Hoboken, N.J.), 2022-02, Vol.74 (2), p.329-341

2022

Volltextzugriff (PDF)

Scleroderma: the role of serum autoantibodies in defining specific clinical phenotypes and organ system involvement

Current opinion in rheumatology, 2014-11, Vol.26 (6), p.646-652

Domsic, Robyn T

2014

Volltextzugriff (PDF)

Managing Symptoms of Systemic Sclerosis for the Allergist-Immunologist

Current allergy and asthma reports, 2024-08, Vol.24 (8), p.433-441

2024

Volltextzugriff (PDF)

Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile

Annals of the rheumatic diseases, 2020-03, Vol.79 (3), p.379-386

2020

Volltextzugriff (PDF)

Development of Pulmonary Hypertension in Over One‐Third of Patients With Th/To Antibody–Positive Scleroderma in Long‐Term Follow‐Up

Arthritis & rheumatology (Hoboken, N.J.), 2022-09, Vol.74 (9), p.1580-1587

2022

Volltextzugriff (PDF)

Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled Trial

American journal of respiratory and critical care medicine, 2021-07, Vol.204 (2), p.209-221

2021

Volltextzugriff (PDF)

Expert consensus on the management of systemic sclerosis-associated interstitial lung disease

Respiratory research, 2023-01, Vol.24 (1), p.6-16, Article 6

2023

Volltextzugriff (PDF)

A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis

Arthritis & rheumatology (Hoboken, N.J.), 2012-09, Vol.64 (9), p.2986-2994

2012

Volltextzugriff (PDF)

A data-driven approach finds RNA polymerase III antibody and tendon friction rubs as enrichment tools for early diffuse scleroderma trials

Rheumatology (Oxford, England), 2023-04, Vol.62 (4), p.1543-1551

2023

Volltextzugriff (PDF)

Treatment of Polymyalgia Rheumatica by Rheumatology Providers: Analysis from the American College of Rheumatology RISE Registry

Arthritis care & research (2010), 2024-02, Vol.76 (2), p.259-264

2024

Volltextzugriff (PDF)

Performance Characteristics of Pulmonary Function Tests for the Detection of Interstitial Lung Disease in Adults With Early Diffuse Cutaneous Systemic Sclerosis

Arthritis & rheumatology (Hoboken, N.J.), 2020-11, Vol.72 (11), p.1892-1896

2020

Volltextzugriff (PDF)

Defining the optimal disease duration of early diffuse systemic sclerosis for clinical trial design

Rheumatology (Oxford, England), 2021-10, Vol.60 (10), p.4662-4670

2021

Volltextzugriff (PDF)

A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers

Arthritis research & therapy, 2019-09, Vol.21 (1), p.202-202, Article 202

2019

Volltextzugriff (PDF)

Over one-third of Th/To antibody positive scleroderma patients develop pulmonary hypertension in long-term follow-up

Arthritis & rheumatology (Hoboken, N.J.), 2022-07, Vol.74 (9), p.1580-1587

2022

Volltextzugriff (PDF)

Patient Perceptions of the Raynaud's Condition Score Diary Provide Insight Into Its Performance in Clinical Trials of Raynaud's Phenomenon: Comment on the Article by Denton et al

Arthritis & rheumatology (Hoboken, N.J.), 2018-06, Vol.70 (6), p.973-974

2018

Volltextzugriff (PDF)

Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma

Annals of the rheumatic diseases, 2011-01, Vol.70 (1), p.104-109

2011

Volltextzugriff (PDF)

Anti–RNPC‐3 (U11/U12) Antibodies in Systemic Sclerosis in Patients With Moderate‐to‐Severe Gastrointestinal Dysmotility

Arthritis care & research (2010), 2019-09, Vol.71 (9), p.1164-1170

2019

Volltextzugriff (PDF)

Skin-Resident Effector Memory CD8+CD28– T Cells Exhibit a Profibrotic Phenotype in Patients with Systemic Sclerosis

Journal of investigative dermatology, 2017-05, Vol.137 (5), p.1042-1050

2017

Volltextzugriff (PDF)

Multinational Qualitative Research Study Exploring the Patient Experience of Raynaud's Phenomenon in Systemic Sclerosis

Arthritis care & research (2010), 2018-09, Vol.70 (9), p.1373-1384

2018

Volltextzugriff (PDF)

Adipose‐Derived Regenerative Cell Transplantation for the Treatment of Hand Dysfunction in Systemic Sclerosis: A Randomized Clinical Trial

Arthritis & rheumatology (Hoboken, N.J.), 2022-08, Vol.74 (8), p.1399-1408

2022

Volltextzugriff (PDF)

Predictive Significance of Serum Interferon‐Inducible Protein Score for Response to Treatment in Systemic Sclerosis–Related Interstitial Lung Disease

Arthritis & rheumatology (Hoboken, N.J.), 2021-06, Vol.73 (6), p.1005-1013

2021

Volltextzugriff (PDF)

Distinct Scleroderma Autoantibody Profiles Stratify Patients for Cancer Risk at Scleroderma Onset and During the Disease Course

Arthritis & rheumatology (Hoboken, N.J.), 2024-01, Vol.76 (1), p.68-77

2024

Volltextzugriff (PDF)

Preventative Care in Scleroderma: What Is the Best Approach to Bone Health and Cancer Screening?

Rheumatic diseases clinics of North America, 2023-05, Vol.49 (2), p.411-423

2023

Volltextzugriff (PDF)

Preventative Care in Scleroderma: What Is the Best Approach to Vaccination?

Rheumatic diseases clinics of North America, 2023-05, Vol.49 (2), p.401-410

2023

Volltextzugriff (PDF)

1 – 25 von 173

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(169)
Mit Volltextzugriff
(139)

Publikationsform

Artikel
(172)
Buchkapitel
(1)

Sprache

Englisch
(173)

Erscheinungsjahr

n.n

Thema

Science & Technology
(128)
Life Sciences & Biomedicine
(127)
Rheumatology
(99)
Humans
(97)
Systemic Sclerosis
(83)
Scleroderma
(75)
Female
(66)
Male
(65)
Middle Aged
(61)
Adult
(50)
Aged
(40)
Scleroderma, Systemic - Complications
(33)
Patients
(24)
Cohort Studies
(22)
Life Sciences
(20)
Lung Diseases
(17)
Severity Of Illness Index
(17)
Pulmonary Hypertension
(15)
Prospective Studies
(14)
Prognosis
(13)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Expansion of Fcγ Receptor IIIa–Positive Macrophages, Ficolin 1–Positive Monocyte‐Derived Dendritic Cells, and Plasmacytoid Dendritic Cells Associated With Severe Skin Disease in Systemic Sclerosis

Scleroderma: the role of serum autoantibodies in defining specific clinical phenotypes and organ system involvement

Managing Symptoms of Systemic Sclerosis for the Allergist-Immunologist

Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile

Development of Pulmonary Hypertension in Over One‐Third of Patients With Th/To Antibody–Positive Scleroderma in Long‐Term Follow‐Up

Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled Trial

Expert consensus on the management of systemic sclerosis-associated interstitial lung disease

A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis

A data-driven approach finds RNA polymerase III antibody and tendon friction rubs as enrichment tools for early diffuse scleroderma trials

Treatment of Polymyalgia Rheumatica by Rheumatology Providers: Analysis from the American College of Rheumatology RISE Registry

Performance Characteristics of Pulmonary Function Tests for the Detection of Interstitial Lung Disease in Adults With Early Diffuse Cutaneous Systemic Sclerosis

Defining the optimal disease duration of early diffuse systemic sclerosis for clinical trial design

A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers

Over one-third of Th/To antibody positive scleroderma patients develop pulmonary hypertension in long-term follow-up

Patient Perceptions of the Raynaud's Condition Score Diary Provide Insight Into Its Performance in Clinical Trials of Raynaud's Phenomenon: Comment on the Article by Denton et al

Survival and Predictors of Mortality in Systemic Sclerosis‐Associated Pulmonary Arterial Hypertension: Outcomes From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry

Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma

Anti–RNPC‐3 (U11/U12) Antibodies in Systemic Sclerosis in Patients With Moderate‐to‐Severe Gastrointestinal Dysmotility

Skin-Resident Effector Memory CD8+CD28– T Cells Exhibit a Profibrotic Phenotype in Patients with Systemic Sclerosis

Multinational Qualitative Research Study Exploring the Patient Experience of Raynaud's Phenomenon in Systemic Sclerosis

Adipose‐Derived Regenerative Cell Transplantation for the Treatment of Hand Dysfunction in Systemic Sclerosis: A Randomized Clinical Trial

Predictive Significance of Serum Interferon‐Inducible Protein Score for Response to Treatment in Systemic Sclerosis–Related Interstitial Lung Disease

Distinct Scleroderma Autoantibody Profiles Stratify Patients for Cancer Risk at Scleroderma Onset and During the Disease Course

Preventative Care in Scleroderma: What Is the Best Approach to Bone Health and Cancer Screening?

Preventative Care in Scleroderma: What Is the Best Approach to Vaccination?

Suchergebnisse filtern